NeOnc Provides Business Update and Reports Q1 2026 Financial Results
NeOnc reported a Q1 2026 net loss of $8.8 million, a significant improvement from the $32.3 million loss in Q1 2025, driven by reduced non-cash stock-based compensation and listing fees. Clinically, the company completed Phase 1 dose-escalation for NEO212, setting the recommended Phase 2 dose at 610 mg, and is preparing for an FDA meeting to discuss a pivotal registrational study. The Phase 2a trial for NEO100 is fully enrolled with interim data expected in August 2026. Liquidity was strengthened by a $10 million PIPE financing anchored by Cinctive Capital and a $10 million undrawn credit line.
Key figures
- Revenue
- 0
- Ga and a
- 488709
- Ga and a yoy
- 849485
- Non cash sbc
- 2732397
- Rnd expenses
- 1286336
- Pipe financing
- 10000000
- Rnd expenses yoy
- 998222
- Undrawn credit line
- 10000000
- Cash and equivalents
- 138601
- Normalized cash opex
- 6087535
- Insider purchase value
- 500000
- Annualized normalized cash opex
- 24400000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.